After more than eight years of research to assess safety and efficacy, Advantage Arrest recently received clearance from the Food and Drug Administration to be marketed, said Dr. Peter Milgrom, scientific director for Advantage Silver in the US. “This is a significant milestone for US dental professionals,” said Milgrom.
“We are extremely excited that the American dental profession will now have the opportunity to provide this proven therapy to their patients,” said Kevin Thomas, managing member of Elevate Oral Care, exclusive distributor of Advantage Arrest.
In a 2010 two-site clinical study, Advantage Arrest was found to significantly reduce dental hypersensitivity (1). The results were clinically superior to results obtained in a 2006 study of Duraphat 5% sodium fluoride varnish (2).
For more information, visit www.elevateoralcare.com or call Elevate at (877) 866-9113.
References
1. Castillo JL, Rivera S, Aparicio T, Lazo R, Aw TC, Mancl LL, Milgrom P. The short-term effects of diamine silver fluoride on tooth sensitivity: a randomized controlled trial. J Dent Res. 2011 Feb;90(2):203-8.
2. Ritter AV, de L Dias W, Miguez P, Caplan DJ, Swift EJ Jr. Treating cervical dentin hypersensitivity with fluoride varnish: a randomized clinical study. J Am Dent Assoc. 2006 Jul;137(7):1013-20; quiz 1029.
